Patents by Inventor Xavier Gallet

Xavier Gallet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified coagulation factor IX polypeptides and use thereof for treatment
    Publication number: 20130243855
    Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
    Type: Application
    Filed: November 14, 2012
    Publication date: September 19, 2013
    Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
  • Modified coagulation factor IX polypeptides and use thereof for treatment
    Patent number: 8383388
    Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: February 26, 2013
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
  • MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20120264686
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: May 29, 2009
    Publication date: October 18, 2012
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Modified erythropoietin polypeptides and uses thereof for treatment
    Patent number: 8252743
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: August 28, 2012
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20120094906
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: May 29, 2009
    Publication date: April 19, 2012
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Modified erythropoietin polypeptides and uses thereof
    Publication number: 20090238789
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: November 28, 2007
    Publication date: September 24, 2009
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Modified coagulation factor IX polypeptides and use thereof for treatment
    Publication number: 20080102115
    Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
    Type: Application
    Filed: June 15, 2007
    Publication date: May 1, 2008
    Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti